KRAS and non-small cell lung carcinoma: Afterward, one study [15] found that TRAIL/DR5 could interact with Rac1/PI3K/AKT and then induce proliferation and metastasis in KRAS‐mutated cells (NSCLC and PDAC tumor cells).